Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects

被引:13
作者
Shiozaki, Tomomi [1 ]
Ueno, Takayo [1 ]
Nagashima, Hirotaka [2 ]
Yamahira, Naomi [1 ]
Hiraoka, Masaki [1 ]
Eley, Tim [3 ]
Bifano, Marc [3 ]
Bertz, Richard J. [3 ]
机构
[1] Bristol Myers KK, Tokyo, Japan
[2] Clin Res Hosp Tokyo, Tokyo Clin Trial Ctr, Tokyo, Japan
[3] Bristol Myers Squibb Res & Dev, Hopewell, NJ USA
关键词
hepatitis C; antiviral; daclatasvir; asunaprevir; pharmacokinetic; Japanese; healthy; NS3 PROTEASE INHIBITOR; HEPATITIS-C; NS5A INHIBITOR; INFECTION; BMS-790052;
D O I
10.5414/CP202186
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Assess the safety, tolerability, and pharmacokinetic (PK) profiles of daclatasvir (DCV) and asunaprevir (ASV) in healthy male Japanese subjects. Methods: AI444-007 and AI447-005 were phase I, double-blind, placebo-controlled, sequential, single-ascending dose (SAD), and multiple-ascending dose (MAD) studies assessing DCV or ASV, respectively. Eight subjects per panel were randomized to study drug or placebo (3 : 1). In the SAD part of each study, subjects received single oral dose DCV 1/10/50/100/200 mg or ASV 200/400/600/900/1,200 mg. In MAD, subjects received 14-day oral multiple dose DCV 1/10/100 mg once-daily or ASV 200/400/600 mg every 12 hours. Serial PK blood sampling occurred from predose to 72-hours postdose or post-last-dose. Safety and tolerability was assessed throughout. Results: 64 (SAD, n = 40; MAD, n = 24) and 65 (SAD, n = 40; MAD, n = 25) subjects were enrolled in AI444-007 and AI447-005, respectively. DCV and ASV were generally well tolerated, with no serious adverse events or clinically-relevant changes in vital signs or ECG parameters. Baseline demographic characteristics were comparable across treatment groups in both studies. DCV was readily absorbed, with median t(max) of similar to 1 - 2 hours postdose and concentrations declining in a multi-phasic manner. Exposure generally increased dose-proportionally within dose-range studied. Steady-state was achieved between days 4 and 5 of multiple dosing. ASV was readily absorbed, with median t(max) of similar to 2 - 4 hours postdose and concentrations declining in a biphasic manner. Exposure generally increased dose-proportionally within dose-range studied. Steady-state appeared to be achieved between days 3 and 5 of multiple dosing. Conclusions: Results suggest no clinically significant short-term safety signals with DCV and ASV at single or multiple doses in this population.
引用
收藏
页码:292 / 300
页数:9
相关论文
共 23 条
[1]   JS']JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1 [J].
Asahina, Yasuhiro ;
Hayashi, Norio ;
Hiramatsu, Naoki ;
Izumi, Namiki ;
Koike, Kazuhiko ;
Kumada, Hiromitsu ;
Kurosaki, Masayuki ;
Oketani, Makoto ;
Suzuki, Fumitaka ;
Takikawa, Hajime ;
Tanaka, Atsushi ;
Tanaka, Eiji ;
Tanaka, Yasuhito ;
Tsubouchi, Hirohito ;
Yotsuyanagi, Hiroshi .
HEPATOLOGY RESEARCH, 2014, 44 :59-70
[2]   Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C [J].
Bronowicki, Jean-Pierre ;
Pol, Stanislas ;
Thuluvath, Paul J. ;
Larrey, Dominique ;
Martorell, Claudia T. ;
Rustgi, Vinod K. ;
Morris, David W. ;
Younes, Ziad ;
Fried, Michael W. ;
Bourliere, Marc ;
Hezode, Christophe ;
Reddy, K. Rajender ;
Massoud, Omar ;
Abrams, Gary A. ;
Ratziu, Vlad ;
He, Bing ;
Eley, Timothy ;
Ahmad, Alaa ;
Cohen, David ;
Hindes, Robert ;
McPhee, Fiona ;
Reilly, Bridget ;
Mendez, Patricia ;
Hughes, Eric .
ANTIVIRAL THERAPY, 2013, 18 (07) :885-893
[3]   EXPOSURE-RESPONSE ANALYSES OF ASUNAPREVIR IN COMBINATION WITH DACLATASVIR ± PEGINTERFERON/RIBAVIRIN AMONG PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION: DOSE SELECTION FOR PHASE 3 CLINICAL TRIALS [J].
Chan, P. ;
Tafoya, E. ;
Eley, T. ;
He, B. ;
Mendez, P. ;
Gardiner, D. ;
Hughes, E. ;
Schnittman, S. ;
Bertz, R. J. .
JOURNAL OF HEPATOLOGY, 2013, 58 :S328-S329
[4]   DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY [J].
Dore, G. J. ;
Lawitz, E. ;
Hezode, C. ;
Shafran, S. ;
Ramji, A. ;
Tatum, H. ;
Taliani, G. ;
Tran, A. ;
Brunetto, M. ;
Zaltron, S. ;
Strasser, S. ;
Weis, N. ;
Ghesquiere, W. ;
Lee, S. ;
Larrey, D. ;
Pol, S. ;
Harley, H. ;
George, J. ;
Fung, S. ;
de Ledinghen, V. ;
Hagens, P. ;
Cohen, D. ;
Cooney, E. ;
Noviello, S. ;
Hughes, E. .
JOURNAL OF HEPATOLOGY, 2013, 58 :S570-S571
[5]   Guidelines for the Management of Hepatitis C Virus Infection [J].
Asahina, Yasuhiro ;
Hayashi, Norio ;
Hiramatsu, Naoki ;
Izumi, Namiki ;
Koike, Kazuhiko ;
Kumada, Hiromitsu ;
Oketani, Makoto ;
Suzuki, Fumitaka ;
Takikawa, Hajime ;
Tanaka, Atsushi ;
Tsubouchi, Hirohito ;
Yotsuyanagi, Hiroshi .
HEPATOLOGY RESEARCH, 2013, 43 (01) :1-34
[6]   Organic Anion Transporting Polypeptide-Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease [J].
Eley, T. ;
Han, Y-H ;
Huang, S-P ;
He, B. ;
Li, W. ;
Bedford, W. ;
Stonier, M. ;
Gardiner, D. ;
Sims, K. ;
Rodrigues, A. D. ;
Bertz, R. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (02) :159-166
[7]   Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C [J].
Eley, Timothy ;
He, Bing ;
Huang, Shu-Pang ;
Li, Wenying ;
Pasquinelli, Claudio ;
Rodrigues, A. David ;
Grasela, Dennis M. ;
Bertz, Richard J. .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04) :316-327
[8]  
Eley T, 2012, HEPATOLOGY, V56, p1070A
[9]   Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection [J].
Everson, Gregory T. ;
Sims, Karen D. ;
Rodriguez-Torres, Maribel ;
Hezode, Christophe ;
Lawitz, Eric ;
Bourliere, Marc ;
Loustaud-Ratti, Veronique ;
Rustgi, Vinod ;
Schwartz, Howard ;
Tatum, Harvey ;
Marcellin, Patrick ;
Pol, Stanislas ;
Thuluvath, Paul J. ;
Eley, Timothy ;
Wang, Xiaodong ;
Huang, Shu-Pang ;
McPhee, Fiona ;
Wind-Rotolo, Megan ;
Chung, Ellen ;
Pasquinelli, Claudio ;
Grasela, Dennis M. ;
Gardiner, David F. .
GASTROENTEROLOGY, 2014, 146 (02) :420-429
[10]   Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect [J].
Gao, Min ;
Nettles, Richard E. ;
Belema, Makonen ;
Snyder, Lawrence B. ;
Nguyen, Van N. ;
Fridell, Robert A. ;
Serrano-Wu, Michael H. ;
Langley, David R. ;
Sun, Jin-Hua ;
O'Boyle, Donald R. ;
Lemm, Julie A. ;
Wang, Chunfu ;
Knipe, Jay O. ;
Chien, Caly ;
Colonno, Richard J. ;
Grasela, Dennis M. ;
Meanwell, Nicholas A. ;
Hamann, Lawrence G. .
NATURE, 2010, 465 (7294) :96-U108